Nanosonics wins NSW Export Award
12 October, 2012 by Dylan Bushell-EmblingNanosonics (ASX:NAN) has been entered as a finalist in the Australian Export Awards, after winning recognition at yesterday's Premier's NSW Export Awards.
Benitec to buy Tacere and its new hepatitis C treatment drug
11 October, 2012 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) will acquire Tacere Therapeutics, which has a phase I/II ready hepatitis C treatment candidate developed using Benitec's ddRNAi technology.
Bionomics chairman to step down
11 October, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has announced that chairman Chris Fullerton will leave the company at the end of the year, and will be replaced by Graeme Kaufman.
AusBiotech Annual Report 2012 details year of significance
11 October, 2012 by AusBiotechThe AusBiotech Annual Report 2012, released this week, details another significant period for AusBiotech and for the Australian biotechnology industry.
QRxPharma scores Canadian licensing deal for MoxDuo
10 October, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has secured a potentially lucrative licensing deal covering the Canadian market for its pain relief drug, MoxDuo IR, which is currently awaiting marketing approval in Canada and the US.
AusBiotech welcomes McKeon Review focus on translation
09 October, 2012 by AusBiotechThe McKean Review has reported recently, providing a consultation paper for comment until the end of October.
Vaxxas partners with Merck on Nanopatch needle-free vaccine patch
09 October, 2012 by Dylan Bushell-EmblingStart-up Vaxxas has picked up its first major pre-licensing and evaluation deal for Nanopatch, the needle-free vaccine technology developed at the AIBN, collaborating with Merck.
AtCor wins $3.2m SphygmoCor deal
08 October, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has won a $3.2 million contract to supply its SphygmoCor specialist blood pressure monitoring systems for multiple clinical trial sites.
Bluechiip cashes in on R&D Tax Incentive
04 October, 2012 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has become the latest life science company to take advantage of the government's R&D Tax Incentive.
Sirtex sales continue to grow
04 October, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has reported another strong quarter for its SIR-Spheres targeted radioactive liver cancer treatments, reporting year-on-year sales growth of 37% for Q1.
AusBiotech submits to Productivity Commission on compulsory licensing
04 October, 2012 by AusBiotechAusBiotech has provided a submission in response to the Productivity Commission’s discussion paper on its review into compulsory licensing in the patents system.
Sunshine Heart to start C-Pulse Heart Assist trial in US
03 October, 2012 by Dylan Bushell-EmblingUS Food and Drug Administration (FDA) conditional approval for an investigational device exemption (IDE) for Sunshine Heart’s (ASX:SHC) flagship C-Pulse Heart Assist System paves the way for the company to conduct a key clinical trial of the system to support its FDA application.
BioDiem launches $2.5m rights issue
02 October, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has commenced an up to $2.5m rights issue to raise funds for its various vaccine and infectious disease development programs.
Vale Nancy Millis AC, Australia’s “first lady” of biotechnology
02 October, 2012 by Tim DeanThe Australian life sciences community is mourning the loss of Emeritus Professor Nancy Millis AC, who passed away this weekend at the age of 90.
AusBiotech & Beacon to partner on key investment events
02 October, 2012 by AusBiotechAusBiotech and Beacon Events, organiser of the largest resource sector investor event in the Asia Pacific Region – Mines and Money – have announced a partnership to deliver biotechnology investor meetings in Hong Kong and Sydney until 2015.
